IPSOGEN to Present Two Studies on the Genomic Grade Test at ASCO 2011 in Chicago, Ill, USA
(Alternext: ALIPS) today announces that two studies on the Genomic Grade test
will be presented at the American Society for Clinical Oncology (ASCO) Annual
Meeting, that will take place
Genomic Grade test (GG), a multi-gene expression test, improves tumor
grading, long term prognostication, and consequently treatment decisions for
women with early invasive hormone receptor positive breast cancer.
The first study has been run prospectively with a network of 8 Belgian
breast cancer centres. The second study, focusing on lobular carcinoma,
results from a collaboration with Institut Jules Bordet, and St Luc Hospital,
different settings, provide additional evidence for the added value of the
Genomic Grade test for tumor grading and, consequently, long term prognosis
Poster Presentation: Genomic grade: Feasibility in routine practice and
influence on treatment decision in early breast cancer (Abstract #606)
– Lead Author: O. Metzger, Be
– Location: McCormick Place Hall A
Poster Presentation and Discussion: Use of genomic grade index to improve
tumor grading of invasive lobular breast carcinoma (Abstract #535)
- Lead Author: D. Fumagalli, Be - June 7, 8:00 am to 12:00 pm - Discussion Time: Tuesday June 7, 11:30 AM to 12:30 PM - Location: McCormick Place E450a
About Genomic Grade
The value of tumor grade as one of the key drivers for long term
prognosis of hormone receptor positive early invasive breast cancer has been
widely documented over the last decade and tumor grade is part of all current
treatment guidelines and decision algorithms. However, assessment of tumor
grade, measured to date by histology, suffers two limitations: 1/variability
of assessment across pathology labs, and 2/presence of an intermediate
category, histologic grade 2, which can represent as much as 50% of tumors
and has a limited informative power for treatment decision making.
The Genomic Grade is addressing these 2 limitations. Proliferation genes
are the main component of the selected gene signature. The added value of
Genomic Grade to identify high and low grade tumors, esp. in histologic grade
2 tumors, has been documented on 3 000 cases. Moreover, Genomic Grade is able
to separate Luminal A and Luminal B tumors.
Genomic Grade is currently available in
Affymetrix micro-array based assay. A PCR version of the test, adapted to
formalin fixed-parafin embedded specimens, is under development and should be
available end 2011.
About Invasive Lobular Carcinoma
Invasive lobular carcinoma, which represents approx. 10% of invasive
breast carcinoma, is the second most common histologic type after ductal
carcinoma. Its management and treatment modalities are similar to those of
However, because of the specific abnormalities characteristising lobular
carcinoma cells, it is particularly difficult to reliably measure tumor grade
with the standard histologic tools. Moreover, up to 80% of lobular carcinoma
are classified as histologic grade 2, an intermediate grade category of
limited informative value. It is therefore difficult to apply the
well-validated treatment decision algorithms -most of them incorporating
tumor grade- for this category of breast carcinoma.
IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests
that help to map diseases and guide patients and oncologists’ decisions along
their therapeutic path.
With more than 80 tests already used routinely worldwide for the
diagnosis, prognosis and follow-up of thousands of patients with leukemia,
IPSOGEN is now targeting breast cancer with the aim of providing currently
inaccessible diagnostic information.
Strengthened by its scientific, clinical and technological partnerships,
and by its multidisciplinary team in
become a world leader in the molecular profiling of cancers, and to continue
the development and promotion of best-in-class diagnostic references that
have a significant impact on patients, medical professionals and society.
The company headquartered in
For further information, visit http://www.ipsogen.com Contacts IPSOGEN Vincent Fert CEO Tel : +33(0)4-9129-3090 email@example.com Helene Peyro-Saint-Paul CMO Tel : +33(0)4-9129-3090 firstname.lastname@example.org Pascale Boissel CFO Tel : +33(0)4-9129-3090 email@example.com ATCG Press NewCap. Corporate and Product Financial communication and Information Investor relations Marielle Bricman Axelle Vuillermet & Pierre Laurent Tel : +33(0)4-9125-0785 Tel : +33(0)1-44-71-94-93 firstname.lastname@example.org email@example.com
SOURCE Ipsogen SA